HRP20210766T1 - Imunoterapija na bazi indoleamin 2, 3-dioksigenaze - Google Patents
Imunoterapija na bazi indoleamin 2, 3-dioksigenaze Download PDFInfo
- Publication number
- HRP20210766T1 HRP20210766T1 HRP20210766TT HRP20210766T HRP20210766T1 HR P20210766 T1 HRP20210766 T1 HR P20210766T1 HR P20210766T T HRP20210766T T HR P20210766TT HR P20210766 T HRP20210766 T HR P20210766T HR P20210766 T1 HRP20210766 T1 HR P20210766T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- peptide
- vaccine
- seq
- adjuvant
- Prior art date
Links
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title claims 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title claims 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 11
- 239000002671 adjuvant Substances 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 108010033276 Peptide Fragments Proteins 0.000 claims 3
- 102000007079 Peptide Fragments Human genes 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020000946 Bacterial DNA Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (14)
1. Pripravak cjepiva, koji sadrži:
a) imunogenski aktivni peptidni fragment indoleamin 2,3-dioksigenaze (IDO) sa SEQ ID NO:1, koji se sastoji od najviše 50 uzastopnih aminokiselina sa SEQ ID NO:1 koje sadrže sekvencu SEQ ID NO:6; i
b) adjuvant.
2. Pripravak cjepiva za primjenu prema zahtjevu 1, što spomenuti imunogenski aktivni peptidni fragment
a) ima najviše 11 aminokiselina u dužini; ili
b) ima od 18 do 30 aminokiselina u dužini.
3. Pripravak cjepiva za primjenu prema zahtjevu 1 ili 2, što spomenuti imunogenski aktivni peptidni fragment sadrži SEQ ID NO:6.
4. Pripravak cjepiva za primjenu prema bilo kojem zahtjevu od 1 do 3, što je adjuvant odabran iz grupe koja se sastoji od GM-CSF-a, adjuvanta na bazi bakterijske DNK, adjuvanta na bazi ulja/surfaktanta, adjuvanta na bazi virusne dsRNK i imidazokinilina.
5. Pripravak cjepiva za primjenu prema zahtjevu 4, što je adjuvant Montanide ISA adjuvant ili GM-CSF.
6. Pripravak cjepiva za primjenu prema zahtjevu 5, što je adjuvant Montanide ISA 51 ili Montanide ISA 720.
7. Izolirani peptid od najviše 50 uzastopnih aminokiselinskih ostataka sa SEQ ID NO:1, koji sadrži sekvencu SEQ ID NO:6.
8. Izolirani peptid prema zahtjevu 7 koji sadrži sekvencu SEQ ID NO:6.
9. Pripravak cjepiva prema bilo kojem zahtjevu od 1 do 6, za upotrebu u postupku za liječenje ili sprječavanje raka.
10. Peptid prema zahtjevu 7 ili 8 za primjenu u postupku za liječenje ili sprječavanje raka.
11. Cjepivo ili peptid za primjenu prema zahtjevu 9 ili 10, što se postupak sastoji od primjene spomenutog cjepiva ili peptida u kombinaciji s dodatnom terapijom protiv raka.
12. Cjepivo ili peptid za primjenu prema zahtjevu 11, što je dodatna terapija protiv raka odabrana iz grupe koja se sastoji od kemoterapije, radioterapije, liječenja imunostimulirajućim sredstvima, genske terapije, liječenja antitijelima i liječenja pomoću dendritičkih stanica.
13. Cjepivo ili peptid za primjenu prema bilo kojem od zahtjeva 10 do 12, što je rak odabran iz melanoma, raka dojke, raka jajnika, raka pluća, raka gušterače, hematoloških karcinoma (kao što su leukemije), raka debelog crijeva i raka bubrežnih stanica.
14. Izolirana nukleinska kiselina koja kodira peptid prema zahtjevu 7 ili 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800565 | 2008-04-17 | ||
| EP17194619.7A EP3320912B1 (en) | 2008-04-17 | 2009-04-17 | Indoleamine 2, 3-dioxygenase based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210766T1 true HRP20210766T1 (hr) | 2021-07-23 |
Family
ID=40873320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180282TT HRP20180282T1 (hr) | 2008-04-17 | 2018-02-15 | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze |
| HRP20210766TT HRP20210766T1 (hr) | 2008-04-17 | 2021-05-13 | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180282TT HRP20180282T1 (hr) | 2008-04-17 | 2018-02-15 | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US9433666B2 (hr) |
| EP (3) | EP3320912B1 (hr) |
| JP (2) | JP2011520783A (hr) |
| CN (2) | CN102088994B (hr) |
| AU (1) | AU2009253539B2 (hr) |
| CA (1) | CA2721150C (hr) |
| CY (2) | CY1120352T1 (hr) |
| DK (2) | DK2280721T3 (hr) |
| ES (2) | ES2657963T3 (hr) |
| HR (2) | HRP20180282T1 (hr) |
| HU (2) | HUE037973T2 (hr) |
| IL (1) | IL208781A (hr) |
| LT (2) | LT2280721T (hr) |
| NO (1) | NO2280721T3 (hr) |
| NZ (1) | NZ588757A (hr) |
| PL (2) | PL2280721T3 (hr) |
| PT (2) | PT3320912T (hr) |
| SI (2) | SI2280721T1 (hr) |
| WO (1) | WO2009143843A1 (hr) |
| ZA (1) | ZA201008056B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015181266A1 (en) * | 2014-05-29 | 2015-12-03 | Spring Bioscience Corporation | Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof |
| CA2959197C (en) * | 2014-09-17 | 2023-03-14 | Herlev Hospital | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
| CN106148276A (zh) * | 2015-04-16 | 2016-11-23 | 中国科学院上海生命科学研究院 | 间充质干细胞在制备治疗神经退行性疾病的药物中的应用 |
| BR112017027653A2 (pt) | 2015-06-29 | 2018-08-28 | Ose Immunotherapeutics | método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos |
| CN116333088A (zh) | 2015-09-16 | 2023-06-27 | Io生物技术公司 | 包含c-c基序趋化因子22（ccl22）或其片段的疫苗组合物 |
| PT3423087T (pt) | 2016-03-04 | 2023-12-28 | Io Biotech Aps | Terapia de cpombinação contra o cancro |
| AU2017276498A1 (en) | 2016-06-10 | 2019-01-03 | Io Biotech Aps | CALR and JAK2 vaccine compositions |
| WO2018067660A1 (en) * | 2016-10-04 | 2018-04-12 | University Of Florida Research Foundation, Inc. | Targeted effector proteins and uses thereof |
| WO2018069494A1 (en) * | 2016-10-14 | 2018-04-19 | Universität Zürich | Indoleamine-2,3-dioxygenase assay for prostate cancer diagnosis and prognosis |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| CR20190388A (es) * | 2017-01-27 | 2019-10-16 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| WO2019075062A1 (en) | 2017-10-11 | 2019-04-18 | University Of Florida Research Foundation | MODIFIED GAL-1 PROTEINS AND USES THEREOF |
| WO2019101347A1 (en) | 2017-11-27 | 2019-05-31 | Ose Immunotherapeutics | Improved treatment of cancer |
| CN109758467B (zh) * | 2019-03-08 | 2020-12-25 | 中国农业科学院兰州兽医研究所 | 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用 |
| AU2020371562A1 (en) * | 2019-10-23 | 2022-06-09 | The Council Of The Queensland Institute Of Medical Research | Adoptive immunotherapy |
| CN112881269A (zh) * | 2021-02-23 | 2021-06-01 | 浙江正熙生物技术股份有限公司 | 一种流式荧光检测试剂的质量检测方法 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| AU6180096A (en) * | 1995-06-20 | 1997-01-22 | Merck & Co., Inc. | Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| JP3676380B2 (ja) | 1996-06-12 | 2005-07-27 | シャンハイ・シーピー・グオジャン・ファーマシューティカル・カンパニー・リミテッド | 細胞性ワクチンおよび免疫療法薬ならびにそれらの製造方法 |
| CN1223688A (zh) * | 1996-06-27 | 1999-07-21 | 纳幕尔杜邦公司 | 对羟基苯丙酮酸双加氧酶的植物基因 |
| DE19730066A1 (de) * | 1997-07-14 | 1999-01-21 | Basf Ag | DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen |
| AU1628599A (en) | 1997-12-05 | 1999-06-28 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan |
| EP1185687A1 (en) | 1999-05-03 | 2002-03-13 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
| WO2002059377A2 (en) | 2001-01-24 | 2002-08-01 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| WO2003012061A2 (en) | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| US7354909B2 (en) | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| US7763251B2 (en) | 2002-04-12 | 2010-07-27 | Medical College Of Georgia Research Institute, Inc. | Kits to assess the risk of tumor progression |
| WO2003087347A1 (en) | 2002-04-12 | 2003-10-23 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004053075A2 (en) | 2002-12-05 | 2004-06-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to breast specific genes and proteins |
| EP1569690B1 (en) | 2002-12-13 | 2011-07-27 | Mitra Medical Technology AB | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
| DE10261223A1 (de) | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| JP2006521377A (ja) | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ｉｄｏ阻害剤とその使用方法 |
| US20050186289A1 (en) | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| WO2005036127A2 (en) | 2003-10-02 | 2005-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying target cell cytolytic lymphocytes in a sample |
| EP1773846A4 (en) * | 2004-07-13 | 2008-10-08 | Univ British Columbia | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| WO2006056304A2 (en) | 2004-11-23 | 2006-06-01 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
| CN101111260B (zh) | 2005-02-04 | 2013-03-20 | 萨瓦克公司 | 存活蛋白肽疫苗 |
| SI1879573T1 (sl) | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
| US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| EP2340847A3 (en) * | 2005-09-23 | 2016-11-09 | Cellerix, S.A. | Cell populations having immunoregulatory activity, method for isolation and uses |
| US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| WO2007115068A2 (en) | 2006-03-30 | 2007-10-11 | Indiana University Research And Technology Corporation | Genetic variants in the indoleamine 2,3-dioxygenase gene |
| WO2008143668A2 (en) * | 2006-05-18 | 2008-11-27 | Lankenau Institute For Medical Research | Indoleamine-2, 3-dioxygenase-2 |
| WO2008085828A2 (en) * | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
-
2009
- 2009-04-17 EP EP17194619.7A patent/EP3320912B1/en active Active
- 2009-04-17 CN CN200980122844.0A patent/CN102088994B/zh active Active
- 2009-04-17 PL PL09753556T patent/PL2280721T3/pl unknown
- 2009-04-17 CA CA2721150A patent/CA2721150C/en active Active
- 2009-04-17 ES ES09753556.1T patent/ES2657963T3/es active Active
- 2009-04-17 SI SI200931791T patent/SI2280721T1/en unknown
- 2009-04-17 HU HUE09753556A patent/HUE037973T2/hu unknown
- 2009-04-17 HU HUE17194619A patent/HUE055338T2/hu unknown
- 2009-04-17 DK DK09753556.1T patent/DK2280721T3/da active
- 2009-04-17 US US12/988,124 patent/US9433666B2/en active Active
- 2009-04-17 WO PCT/DK2009/000095 patent/WO2009143843A1/en active Application Filing
- 2009-04-17 EP EP21157371.2A patent/EP3915570A1/en active Pending
- 2009-04-17 DK DK17194619.7T patent/DK3320912T3/da active
- 2009-04-17 JP JP2011504314A patent/JP2011520783A/ja active Pending
- 2009-04-17 LT LTEP09753556.1T patent/LT2280721T/lt unknown
- 2009-04-17 SI SI200932129T patent/SI3320912T1/sl unknown
- 2009-04-17 CN CN201410247727.XA patent/CN104056261B/zh active Active
- 2009-04-17 EP EP09753556.1A patent/EP2280721B1/en active Active
- 2009-04-17 LT LTEP17194619.7T patent/LT3320912T/lt unknown
- 2009-04-17 PT PT171946197T patent/PT3320912T/pt unknown
- 2009-04-17 PL PL17194619T patent/PL3320912T3/pl unknown
- 2009-04-17 NZ NZ588757A patent/NZ588757A/en unknown
- 2009-04-17 NO NO09753556A patent/NO2280721T3/no unknown
- 2009-04-17 ES ES17194619T patent/ES2870596T3/es active Active
- 2009-04-17 AU AU2009253539A patent/AU2009253539B2/en active Active
- 2009-04-17 PT PT97535561T patent/PT2280721T/pt unknown
-
2010
- 2010-10-17 IL IL208781A patent/IL208781A/en active IP Right Grant
- 2010-11-10 ZA ZA2010/08056A patent/ZA201008056B/en unknown
-
2015
- 2015-03-17 JP JP2015052888A patent/JP6016966B2/ja active Active
-
2016
- 2016-08-08 US US15/231,075 patent/US10258678B2/en active Active
-
2018
- 2018-02-12 CY CY20181100171T patent/CY1120352T1/el unknown
- 2018-02-15 HR HRP20180282TT patent/HRP20180282T1/hr unknown
-
2019
- 2019-01-29 US US16/261,114 patent/US11324813B2/en active Active
-
2021
- 2021-05-13 HR HRP20210766TT patent/HRP20210766T1/hr unknown
- 2021-06-28 CY CY20211100572T patent/CY1124279T1/el unknown
-
2022
- 2022-03-17 US US17/697,732 patent/US20220202922A1/en not_active Abandoned
- 2022-04-15 US US17/721,577 patent/US11648302B2/en active Active
-
2023
- 2023-04-10 US US18/298,263 patent/US20230233657A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210766T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
| MX2018009126A (es) | Vectores virales oncoliticos y usos de estos. | |
| PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| SI2197481T1 (en) | RNA compositions for the treatment of non-small cell lung cancer (NDCPR) | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| NZ586238A (en) | Methods and compositions for immunizing pigs against porcine circovirus | |
| NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| NZ610376A (en) | North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof | |
| RU2019107976A (ru) | Композиция вакцины | |
| BR112014028787A2 (pt) | método para tratamento de câncer de pulmão de célula não pequena | |
| EP2574170A4 (en) | IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS | |
| MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| MX2022005704A (es) | Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b. | |
| ES2566146T3 (es) | Virus de ARN oncolítico genéticamente estable, método de fabricación y uso del mismo | |
| BR112012025567A2 (pt) | peptídeos de cdca5 e vacinas que incluem os mesmos | |
| EA201990719A1 (ru) | Новые промоторы | |
| MX2021010862A (es) | Arn terapeutico para el cancer de prostata. | |
| NZ609440A (en) | Preventative or therapeutic agent for fibrosis | |
| UA102274C2 (ru) | Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| RU2016141287A (ru) | Не встречающийся в природе вирус репродуктивно-респираторного синдрома свиней (bppcc) и способы применения | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| TW200801034A (en) | Novel sea lice vaccine |